{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"77.4","value":"33.3"},{"groupId":"OG001","lowerLimit":"5.8","upperLimit":"84.5","value":"50.0"},{"groupId":"OG002","lowerLimit":"4.6","upperLimit":"67.6","value":"33.3"},{"groupId":"OG003","lowerLimit":"27.0","upperLimit":"57.8","value":"42.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"40"}],"units":"Participants"}],"description":"PFS-6 according to RECIST 1.1 is the primary endpoint in Phase 2 and a secondary endpoint in Phase 1, where PFS is measured from the date of the first dose of study treatment to the date of earliest disease progression or to the date of death, if disease progression does not occur. Per RECIST 1.1, progressive disease (PD) is defined as a ≥ 20% increase in the sum of the longest diameter of target lesions (Eisenhauer et al 2009).","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects received PLD (40 mg/m\\^2 IV on Day 1 of every cycle) + durvalumab (3 mg/kg Q2W \\[equivalent to 450 mg Q4W\\] IV on Days 3 and 17 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m\\^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Days 3 and 17 of Cycles 4-12.","id":"OG000","title":"Phase 1, Dose Level 0a"},{"description":"Subjects received PLD (40 mg/m\\^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.0 mg/m\\^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.","id":"OG001","title":"Phase 1, Dose Level 0b"},{"description":"Subjects received PLD (40 mg/m\\^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m\\^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.","id":"OG002","title":"Phase 1, Dose Level +1"},{"description":"Subjects received the MTD determined in Phase 1, comprising PLD (40 mg/m\\^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment.","id":"OG003","title":"Phase 2"}],"paramType":"NUMBER","populationDescription":"The population comprises all subjects who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to 6 months for each subject","title":"Progression-free Survival Rate at 6 Months (PFS-6) by the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Estimated Using the Kaplan-Meier Method","type":"PRIMARY","unitOfMeasure":"percentage of participants"}